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Abstract
Background: UK Government expenditure on combatting drug abuse is based on estimates of
illicit drug users, yet the validity of these estimates is unknown. This study aims to assess the face
validity of problematic drug use (PDU) and injecting drug use (IDU) estimates for all English Drug
Action Teams (DATs) in 2001. The estimates were derived from a statistical model using the
Multiple Indicator Method (MIM).
Methods: Questionnaire study, in which the 149 English Drug Action Teams were asked to
evaluate the MIM estimates for their DAT.
Results: The response rate was 60% and there were no indications of selection bias. Of responding
DATs, 64% thought the PDU estimates were about right or did not dispute them, while 27% had
estimates that were too low and 9% were too high. The figures for the IDU estimates were 52%
(about right), 44% (too low) and 3% (too high).
Conclusion: This is the first UK study to determine the validity estimates of problematic and
injecting drug misuse. The results of this paper highlight the need to consider criterion and face
validity when evaluating estimates of the number of drug users.
Background
The UK Government's direct annual expenditure on com-
bating illicit drug use is £1.48 billion [1] (2005/2006). By
2007/08, expenditure on treatment will increase to £478
million from £253 million in 2004 [2]. By 2008, the Gov-
ernment's target is to have the capacity to treat 200,000
drug users [3]. However, direct methods of ascertaining
the number of problematic drug users in the country are
unlikely to yield accurate figures. This is because of multi-
ple response bias affecting the likelihood of problem drug
users a) living in a household that would be included in a
sample survey, b) agreeing to participate in a sample sur-
vey and c) reporting recent problem drug use [4,5]. One
alternative method which has been recommended for
country wide prevalence estimates is the Multiple Indica-
tor Method (MIM) [6]. This method combines informa-
tion on prevalence that is available only in a few areas (the
'anchor points') and drug indicators (e.g. number of
crimes, seizures) that are available in all areas [7]. We pre-
viously reported a MIM analysis for all Drug Action Team
(DAT) areas in England for 2001 [8]. The MIM involved a
three stage process: a) factor analysis of the drug indica-
tors, b) regression analysis linking factor scores to
"known" prevalence estimates and c) imputation of esti-
mates in all other DATs. The "known" estimates are
obtained by a technique known as capture-recapture. The
capture-recapture method (CRM) involves 'capturing' a
random sample who are then 'marked' and returned to
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their habitat [9]. Subsequently, a second random sample
are 'recaptured' and the number of marked animals from
the first sample are observed. The ratio of marked animals
to the recaptured sample size is assumed to be the same as
the ratio of the first captured sample to the total popula-
tion. Thus, if a 'capture' sample of 200 animals are marked
and released and a 'recapture' sample of 100 contains 10
animals which are marked, the estimate for the total pop-
ulation would be 2,000 (i.e. 10:100 = 200:2,000). In drug
use studies the samples are lists of drug users whose iden-
tifiers are recorded by agencies such as treatment centres
or the police. More sophisticated versions involving mul-
tiple samples have also been developed in order to over-
come the stringent assumptions which are required when
only two-samples are used [10].
In the MIM study, the regression model explained 32% of
the variance for the problematic anchor points and 70%
for the injecting anchor points. The median estimates
were 287,670 problematic drug users and 93,185 inject-
ing drug users in England in 2001. The definition of prob-
lematic drug use was 'current use of illicit opiates, crack-
cocaine or benzodiazepines'. The definition of injecting
drug use was 'current use of any illicit drug where injecting
was the method of drug administration'. These definitions
are based on the data collection procedures of those
organizations whose data is used in capture-recapture
studies. These organizations consist of drug treatment
agencies, the police, HIV-test registers and needle and
syringe exchanges. As most of these agencies categorise
drug users simply as being current users at time of contact,
it is not possible to give a more precise timeframe.
Validity of drug user estimates
As the MIM estimates are based on a statistical model it is
important to determine the validity of the results. In other
words, does the model correspond to how many prob-
lematic and injecting drug users there actually are in each
DAT? The issue may be addressed in two ways. Firstly, by
comparing the MIM estimates to other prevalence estima-
tion techniques. This is known as criterion-related valid-
ity, which may be defined as "comparing values with one
or more external criteria, known or believed to measure
the attribute under study" [11]. The second method is to
ask experts in each of the DATs to evaluate the MIM esti-
mates. This is referred to as face validity, which is the
degree to which something appears to measure what it is
supposed to measure. While in statistical terms, this is a
weaker form of validity, in practical terms it is important
to practitioners in the field. In 1993, Reuter argued that
prevalence estimates in the United States were not widely
used because of policy-makers' perception of their limited
credibility [12]. However, the situation has changed over
the last decade with the introduction of more scientific
approaches to the simulation of hidden population [13].
In the UK prevalence estimates are increasingly used in the
policy process, for example in relation to the introduction
and placement of syringe exchange programmes [14] and
modelling HIV prevalence [15]. The Government's
Updated Drug Strategy 2002 explicitly aims to increase
the proportion of the "estimated 250,000 problematic
drug users" who receive treatment by 2008 [3].
With regard to criterion-related validity, we have previ-
ously estimated the number of drug users in England,
Wales and Scotland in 1996 using a variety of methods
corresponding to different forms of drug use [16].
Between 1996 and 2001, the MIM estimate for England
increased by 27.6% while a range of drug indicators
increased by an average of 18%. This suggests that the
2001 MIM estimates have acceptable criterion-related
validity.
To the best of our knowledge there has only been one pre-
vious study into face validity of drug user estimates. Fried-
man et al [17] estimated the number of injecting drug
users for 96 metropolitan areas in the USA in 1996 using
a variety of multiplier methods similar to those described
above. They assessed validity by asking 143 experts to
comment on studies or estimates available for their areas.
Of the valid responses, 81% endorsed the estimates, 8%
though the estimates were too low and 11% thought they
were too high. These results suggest that the indicator
methods used in the American study had a high degree of
construct and/or face validity.
The aim of the current study is to determine the face valid-
ity of the 2001 MIM estimates of problematic drug use
(PDU) and injecting drug use (IDU) for the 149 DATS in
England.
Methods
All DATs in England were sent a letter from the Home
Office informing them of this study and that all DATs
were being asked to respond to a questionnaire. Each DAT
was provided with information specific to their area and
told that the aim of the exercise was to gain a broad under-
standing of how DATs view the PDU and IDU estimates.
The questionnaire was kept short, so as to ensure as high
a response rate as possible.
The questionnaire, in Adobe PDF format was emailed to
each DAT by the Home Office via the Regional Managers
on 21st June 2004. It was requested that the questionnaire
be completed by the person (or persons) best placed to
assess the number of drug users in the DAT. The return
date for the questionnaire was 9th  July 2004; non-
responders were followed up at the end of July.BMC Public Health 2007, 7:286 http://www.biomedcentral.com/1471-2458/7/286
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Results
Response rate
90 of the 149 DATs returned the form by 29th July 2004,
giving a response rate of 60.4%. Responders and non-
responders did not differ significantly in terms of their
mean DAT populations (320,674 vs. 313,707, t = 0.17, p
= 0.86). Responders did not significantly differ from non-
responders in terms of their estimated PDU rate (PDU
665 vs. 621 per 100,000 population, x2 = 1.51, p = 0.21).
Evaluation of PDU and IDU estimates
The first question asked was "In your view, is this esti-
mated number of problematic users for your DAT in 2001
A) about right, B) too low, C) too high, D) don't know, E)
other (specify) [Note: we did not provide definitions of
"about right", "too low" or "too high". For this and subse-
quent questions, the percentages refer to responding
DATs.]
PDU estimates
Table 1 shows the DATs' evaluation of the MIM PDU esti-
mates. 76% of responding DATs had an opinion of the
PDU estimates. Around one third of DATs thought the
estimate was about right, while another third thought
they were too low. In the light of this finding, we investi-
gated whether DAT perceptions were related to the esti-
mated PDU rate. There was little variation between the
groups of DATs (F = 0.23, p = 0.86). There is no indication
that DATs who said their estimate was too low came from
especially high prevalence areas.
IDU estimates
The second question asked "In your view, is this estimated
number of injecting drug users for your DAT in 2001 – A)
about right, B) too low, C) too high, D) don't know, E)
other (specify). Table 2 shows how DATs evaluated their
MIM IDU estimates. Among responding DATs, 73%
expressed an opinion about their DAT estimate. 23% of
DATs thought the IDU estimates were "about right".
Compared to PDU evaluation, more DATs thought that
the IDU estimate was too low (46% vs. 32%). There were
no significant differences in terms of DATs' IDU preva-
lence rate (F = 0.78, p = 0.50, n.s.)
Further analysis of Problematic Drug Use (PDU)
Of the 60 DATs who said their PDU estimates were either
too low, too high or don't know, 33 (55%) provided some
free text information to clarify this assessment.
Information provided includes:
• too low (n = 18): other research; data provided by the
National Treatment Agency (NTA); own experience
• too high (N = 7): errors in model figures; too high rela-
tive to numbers on treatment; estimates derived from the
British Crime Survey (BCS)
• don't know/other (N = 8): can't comment; no data; not
in post in 2001
The basis of estimates included: research study (e.g. cap-
ture-recapture, economic modelling); need assessments;
extrapolation from number in treatment, number of
arrests; extrapolation from the British Crime Survey.
Further analysis of Injecting Drug Use (IDU)
Of the 69 DATs who said their IDU estimates were either
too low, too high or don't know, 37 (53%) provided some
free text information to clarify this assessment.
Information provided included:
• too low (n = 27): figures suggest service capacity rather
than actual figure; perception, based on proportion of
problematic users who are injectors; model figures wrong
• too high (N = 2): local research; perception that smok-
ing more common
• don't know/other (N = 8): can't comment; no data; not
in post in 2001
Table 1: Drug Action Teams' evaluation of Problematic Drug User (PDU) estimates
Frequency Percent Valid Percent Percent excluding
 "don't know"
Mean PDU Estimate
 per 100,000 population
1.00 about right 30 20 33 44 661
2.00 too low 29 19 32 43 676
3.00 too high 9 6 10 13 610
4.00 don't know 22 15 24 679
Total 90 60 100 100 665
Missing 59 40
Total 149 100BMC Public Health 2007, 7:286 http://www.biomedcentral.com/1471-2458/7/286
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Figure 1 shows the geographical distribution of DATs' per-
ception of their MIM estimate for problematic drug use.
Comparison of DATs own PDU estimates and the MIM 
PDU estimates
Figure 2 shows that where DATs had PDU estimates of
their own, they tended to be higher than their correspond-
ing MIM estimates. However, it should be noted that the
basis of these estimates require careful evaluation (e.g.
methodology, target population, time period). In many
cases DATs' own estimates may not be directly compara-
ble with the MIM estimates.
6 of the 42 DATs (14%) who thought their MIM estimate
were either 'too low' or 'too high' compared to the MIM
estimate, actually had estimates within 10% of the MIM
estimate.
Comparison of DATs own IDU estimates and the MIM IDU 
estimates
As with PDU, where DATs had their own IDU estimates
(N = 38) they tended to be higher than the MIM estimates.
Two DATs who thought that their MIM IDU estimate were
either 'too high' or 'too low', provided an estimate of their
own that was within 10% of the MIM estimate.
Evaluation of drug indicators
There were many reasons why DATs' own estimates/fig-
ures diverged from the MIM indicators. For example some
DATs thought that indicator S31-refers to all people cur-
rently in treatment. This would account for the fact that
for this indicator, 35 DATs thought the MIM figure was
too low. In fact the MIM indicator refers to people enter-
ing treatment [Number of individuals aged 18+ with
addresses in the DAT area recorded by RDMD as having
entered treatment during 2000/2001].
In contrast, the majority of DATs thought that the MIM
possession and supply figures were too high. One DAT
suggested that their figure was a concatenation of 3 years
figures. For five of the indicators, more DATs (who
expressed an opinion) though that the indicators were
"about right" as opposed too low/high.
Some DATs thought the methadone prescription figures
were too low. These DATs had access to data on metha-
done prescriptions, but our data refer only to prescrip-
tions issued in primary care. Where prescriptions are
issued in secondary care, they would not be included in
our data source.
These ambiguities could possibly have been reduced had
the questionnaire provided more detail. However, there
was concern that providing this information would have
inhibited some DATs from responding. DATs were told
that the further information on the indicators was con-
tained in the full report which could be accessed online
[18].
Further comments on the estimates and indicators
44 DATs provided comments on the form. These covered
a wide range of themes. Some DATs were anxious that
estimates were wrong because of wrong input data. As
explained above, this might have been due to misinterpre-
tation of which data were actually used in the estimation
process. Some DATs were concern that definition of PDU
did not cover PDU as perceived in DAT area. This is a fair
comment, but needs to be seen in the context of providing
uniform estimates across all English DATs. Some DATs
felt that it was difficult to comment on the situation in
2001 or that the relevancy of 2001 estimates was ques-
tionable. Finally some DATs were appreciative of the esti-
mates and wished to be more directly involved in future
estimation work.
Discussion
Main findings of this study
The MIM pilot study provided all DATs with estimates of
the prevalence of problem drug use and injecting drug use
in their area. Among responding DATs (N = 90, response
rate = 60%), 33% thought the PDU estimates were "about
right", while 24% were unable to make an assessment. A
further 6 (7%) DATs who rated the MIM estimates as
Table 2: Drug Action Teams' evaluation of Injecting Drug User (IDU) estimates
Frequency Percent Valid Percent Percent excluding 
"don't know"
Mean IDU Estimate 
per 100,000 population
1.00 about right 21 14 23 32 306
2.00 too low 41 28 46 62 234
3.00 too high 4 3 4 6 300
4.00 don't know 24 16 27 220
Total 90 60 100 100 250
Missing 59 40
Total 149 100BMC Public Health 2007, 7:286 http://www.biomedcentral.com/1471-2458/7/286
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Drug Action Teams' perception of the Multiple Indicator Method (MIM) estimate of problematic drug use (PDU) Figure 1
Drug Action Teams' perception of the Multiple Indicator Method (MIM) estimate of problematic drug use (PDU).BMC Public Health 2007, 7:286 http://www.biomedcentral.com/1471-2458/7/286
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being too low/high provided their own estimate which
was actually within 10% of the MIM estimate. By combin-
ing the three categories: "about right", "don't knows" and
"within 10%", 64% thought the PDU estimates were
about right or did not dispute them [The 'didn't know'
DATs have been included on the basis that they had no
local knowledge with which to make a comparison and
therefore the MIM estimate is an improvement on no
knowledge.]
Among responding DATs (n = 90, response rate = 60%),
23% thought the IDU estimates were "about right", while
27% were unable to make an assessment. A further 2 (2%)
DATs who rated the MIM estimates as being too low/high
provided their own estimate which was actually within
10% of the MIM estimate. Thus, by combining "about
right", "don't knows" and "within 10%", 52% of DATs
have potentially acceptable IDU estimates.
Of the 31 DATs who had their own PDU estimates, 24 of
these were higher than the MIM estimate while 7 were
lower. Of the 20 DATs who had their own IDU estimates,
17 of these were higher than the MIM estimate while 3
were lower. As noted above these estimates may not be
comparable with the MIM estimates. Nevertheless, the
reasons for so many DATs having higher estimates
requires further investigation.
What this study adds
This is the first study to determine the validity of estimates
of problematic drug use in the UK. 64%/52% of the DATs
thought the PDU/IDU estimates were about right or did
not dispute them. However, these figures are lower if the
"don't knows" are excluded (40% and 25% respectively),
and further work is needed to determine the reasons for
this discrepancy.
Limitations of the study
Many comments were received on the validity and relia-
bility of the indicators. For example, most DATs thought
the indicator on the number in treatment was too low,
that the possession and supply indicators were too high,
that arrest referral and drug related deaths were about
right, and did not know about methadone referrals or
deprivation. Clearly, if there is heterogeneity in the com-
pleteness of accuracy of indicators this will add bias to the
MIM estimates, and this may be a potential explanation
for why the MIM estimates were considered too low or too
high. For example, the MIM study indicated that in one
particular DAT there were no IDUs, while the DAT itself
reported in excess of 100 needle exchange attendances.
Conclusion
Given that public health expenditure on illicit drug use is
based on estimates of the scale of the problem, validation
should be an inherent feature of prevalence estimation
studies. Recently, researchers have estimated problematic
drug use for all DATs in England using capture-recapture
for all DATs (except for a few where sufficient data were
not available). The definition of problematic drug use was
use of opiates and/or the use of crack cocaine which is nar-
rower than the definition used in the MIM study (which
also included benzodiazepines). The estimate for the
median number of problematic drug users in England for
2004/5 was 327,466 [19]. This figure represents a 14%
increase on the 2001 MIM study. However, between 2001
and 2005 the rate of self-reported class A drug use in the
last month among people aged 16–59 in the population
dropped by 14% [20] and the number of drug related
deaths declined by 10% [21]. These figures suggest that
problematic drug use in England declined between 2001
and 2005.
These findings have implications for future studies as
there are two approaches to prevalence estimation for
English DATs. The first approach would involve conduct-
ing capture-recapture studies for all DATs. The second
approach would involve conducting capture-recapture
studies in a small number of DATs and using the MIM to
estimate prevalence for remaining DATs. The results of
this paper highlight the need to consider criterion and face
validity when evaluating estimates of the number of drug
users.
Drug Action Teams' own PDU estimates (Y axis) and the  Multiple Indicator Method-Problematic Drug Use (MIM  PDU) estimate (X axis) Figure 2
Drug Action Teams' own PDU estimates (Y axis) and the 
Multiple Indicator Method-Problematic Drug Use (MIM 
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